◆英語タイトル:Anavex Life Sciences Corp (AVXL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013546
◆発行会社(調査会社):
GlobalData
◆発行日:2017年11月28日
◆ページ数:42
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Anavex Life Sciences Corp (Anavex) is a clinical-stage biopharmaceutical company that focuses on developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, other central nervous system (CNS) diseases, pain and various types of cancer. The company’s target indications include Alzheimer’s disease, Parkinson’s disease, Rett syndrome, epilepsy, neuropathic pain, depression, prostate cancer, pancreatic cancer and malignant melanoma. Its pipeline comprises one drug candidate and several compounds in diverse stages of pre-clinical study. Anavex’s lead compound ANAVEX 2-73 is being developed for the treatment of Alzheimer’s disease, Parkinson’s disease and potentially other CNS diseases, including rare diseases. Anavex is headquartered in New York, the US.
Anavex Life Sciences Corp (AVXL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Anavex Life Sciences Corp, Medical Devices Deals, 2011 to YTD 2017 10
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Anavex Life Sciences Enters into Partnership with Ariana Pharmaceuticals 12
Anavex Enters Into Agreement With Roskamp Institute To Develop ANAVEX PLUS 13
Licensing Agreements 14
Anavex Enters Into Licensing Agreement With Life Science Research Israel 14
Equity Offering 15
Anavex Life Sciences Files Registration Statement for Public Offering of Shares for up to USD29 Million 15
Anavex Life Sciences Files Registration Statement for Public Offering of Shares for up to USD100 Million 16
Anavex Life Sciences to Raise USD0.5 Million in Private Placement of Shares and Warrants 17
Anavex Life Sciences Announces Private Placement Of Units For US$2.6 Million 18
Anavex Life Sciences Completes First Tranche Of Private Placement Of Shares For US$0.1 Million 19
Anavex Life Sciences Raises US$1.6 Million Upon Exercise Of Warrants 20
Debt Offering 21
Anavex Life Sciences Completes Private Placement Of Debenture For US$10 Million 21
Anavex Life Sciences Corp – Key Competitors 22
Anavex Life Sciences Corp – Key Employees 23
Anavex Life Sciences Corp – Locations And Subsidiaries 24
Head Office 24
Recent Developments 25
Financial Announcements 25
Aug 07, 2017: Anavex Reports Fiscal Third Quarter 2017 Financial Results 25
May 10, 2017: Anavex Reports Fiscal Second Quarter 2017 Financial Results 27
Feb 07, 2017: Anavex Reports Fiscal First Quarter 2017 Financial Results 28
Aug 11, 2016: Anavex Reports Fiscal Third Quarter 2016 Financial Results 29
May 11, 2016: Anavex Reports Fiscal Second Quarter 2016 Financial Results 30
Feb 08, 2016: Anavex Reports Fiscal First Quarter 2016 Financial Results 31
Corporate Communications 32
Jul 20, 2017: Anavex Life Sciences appoints scientific advisory board member 32
May 01, 2017: Anavex Life Sciences Appoints Former FDA Officer as Senior Vice President of Regulatory Affairs 33
Feb 13, 2017: Anavex Life Sciences Strengthens Board of Directors 34
Legal and Regulatory 35
Mar 30, 2017: Anavex Life Sciences Reports Dismissal of Appeal in the Cortina Lawsuit 35
Jan 03, 2017: Anavex Life Sciences Obtains Permanent Dismissal of All Claims in Securities Lawsuit 36
Product News 37
Nov 21, 2017: Anavex Life Sciences Reports Newly Published Data on Alzheimer’s Disease Research Demonstrate the Neuroprotective Features of the Sigma-1 Receptor 37
Clinical Trials 38
Mar 10, 2016: Anavex Announces Two-Year Clinical Extension Study of ANAVEX 2-73 and Presents Phase 2a Dose-Response Analysis at AAT Conference 38
Feb 25, 2016: Anavex Presents Preclinical Results of ANAVEX 2-73 in Rett Syndrome 39
Feb 17, 2016: ANAVEX 2-73 Preclinical Data in New Indication to be Presented at ACTRIMS 2016 40
Jan 11, 2016: Anavex Announces Positive Dose-Response Data for ANAVEX 2-73 in Alzheimer Disease Patients 41
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42
List of Tables
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Anavex Life Sciences Corp, Deals By Therapy Area, 2011 to YTD 2017 9
Anavex Life Sciences Corp, Medical Devices Deals, 2011 to YTD 2017 10
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Anavex Life Sciences Enters into Partnership with Ariana Pharmaceuticals 12
Anavex Enters Into Agreement With Roskamp Institute To Develop ANAVEX PLUS 13
Anavex Enters Into Licensing Agreement With Life Science Research Israel 14
Anavex Life Sciences Files Registration Statement for Public Offering of Shares for up to USD29 Million 15
Anavex Life Sciences Files Registration Statement for Public Offering of Shares for up to USD100 Million 16
Anavex Life Sciences to Raise USD0.5 Million in Private Placement of Shares and Warrants 17
Anavex Life Sciences Announces Private Placement Of Units For US$2.6 Million 18
Anavex Life Sciences Completes First Tranche Of Private Placement Of Shares For US$0.1 Million 19
Anavex Life Sciences Raises US$1.6 Million Upon Exercise Of Warrants 20
Anavex Life Sciences Completes Private Placement Of Debenture For US$10 Million 21
Anavex Life Sciences Corp, Key Competitors 22
Anavex Life Sciences Corp, Key Employees 23